Bevacizumab effectiveness and primary tumor location in metastatic colorectal cancer patients.

被引：0
|
作者：
He, Wen-zhuo
Yang, Qiong
Jiang, Chang
Liao, Fang-xin
Liu, Shou-sheng
Xia, Liang-ping
机构：
[1] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou 510275, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Oncol, Guangzhou 510275, Guangdong, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 04期
关键词：
D O I：
10.1200/jco.2016.34.4_suppl.683
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
683
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Primary tumor location and bevacizumab effectiveness in metastatic colorectal cancer patients.
    He, Wen-zhuo
    jiang, Chang
    Liao, Fang-xin
    Yang, Qiong
    Kong, Peng-fei
    Xia, Liang-ping
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer
    Boisen, M. K.
    Johansen, J. S.
    Dehlendorff, C.
    Larsen, J. S.
    Osterlind, K.
    Hansen, J.
    Nielsen, S. E.
    Pfeiffer, P.
    Tarpgaard, L. S.
    Hollander, N. H.
    Keldsen, N.
    Hansen, T. F.
    Jensen, B. B.
    Jensen, B. V.
    ANNALS OF ONCOLOGY, 2013, 24 (10) : 2554 - 2559
  • [3] Bevacizumab effectiveness and tumor vessel subtypes in metastatic colorectal cancer patients.
    He, Wen-zhuo
    Jiang, Chang
    Yang, Qiong
    Liao, Fang-xin
    Hu, Wan-ming
    Xia, Liang-ping
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] Primary Tumor Location as a Predictive Factor for First-line Bevacizumab Effectiveness in Metastatic Colorectal Cancer Patients
    He, Wen-Zhuo
    Liao, Fang-Xin
    Jiang, Chang
    Kong, Peng-Fei
    Yin, Chen-Xi
    Yang, Qiong
    Qiu, Hui-Juan
    Zhang, Bei
    Xia, Liang-Ping
    JOURNAL OF CANCER, 2017, 8 (03): : 388 - 394
  • [5] Primary tumor location and expression of mir-664 as a combined biomarker for bevacizumab effectiveness in metastatic colorectal cancer
    Boisen, Mogens Karsboel
    Dehlendorff, Christian
    Linnemann, Dorte
    Larsen, Jim S.
    Oesterlind, Kell
    Hansen, Joergen
    Nielsen, Svend Erik
    Pfeiffer, Per
    Tarpgaard, Line Schmidt
    Hollander, Niels Henrik
    Keldsen, Nina
    Hansen, Torben
    Jensen, Brita Bjerregaard
    Hoegdall, Estrid Vilma Solyom
    Jensen, Benny Vittrup
    Johansen, Julia S.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] Comparative Effectiveness of Bevacizumab versus Cetuximab in Metastatic Colorectal Cancer Patients without Primary Tumor Resection
    Su, Yi-Chia
    Wu, Chih-Chien
    Su, Chien-Chou
    Hsieh, Meng-Che
    Cheng, Ching-Lan
    Kao Yang, Yea-Huei
    CANCERS, 2022, 14 (09)
  • [7] Systemic treatment and primary tumor location in patients with metastatic colorectal cancer
    Antoniou, Efstathios
    Andreatos, Nikolaos
    Margonis, Georgios A.
    Papalois, Apostolos
    Wang, Jaeyun
    Damaskos, Christos
    Garmpis, Nikolaos
    Buettner, Stefan
    Deshwar, Amar
    Pappas, Vasilios
    Weiss, Matthew J.
    Pawlik, Timothy M.
    Pikoulis, Emmanouel
    JOURNAL OF BUON, 2017, 22 (06): : 1447 - 1456
  • [8] Primary Tumor Sidedness Predicts Bevacizumab Benefit in Metastatic Colorectal Cancer Patients
    You, Xia-Hong
    Wen, Can
    Xia, Zi-Jin
    Sun, Fan
    Li, Yao
    Wang, Wei
    Fang, Zhou
    Chen, Qing-Gen
    Zhang, Lei
    Jiang, Yu-Huang
    Wang, Xiao-Zhong
    Ying, Hou-Qun
    Zong, Zhen
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [9] Tumor location in patients with colorectal cancer treated with bevacizumab
    Teresa, Delgado Urena Ma
    Beatriz, Gonzalez-Astorga
    Alvarez Marta, Legeren
    Patricia Maria, Moreno Raya
    Cebrian Irene, Gonzalez
    Montosa Fernando, Galvez
    Carlos Jose, Rodriguez Gonzalez
    Vargas Marisol, Yelamos
    Jose Miguel, Jurado Garcia
    ANNALS OF ONCOLOGY, 2017, 28
  • [10] Can tumor location predict effectiveness of bevacizumab conducted in the first-line setting for metastatic colorectal cancer
    You, K. Y.
    Gao, Y. H.
    ANNALS OF ONCOLOGY, 2014, 25 (02) : 545 - 546
12345